SESSION 2

DIAGNOSIS AND PROGNOSIS

P. Žák, M. Lucijanić

9:20 - 9:30

Welcome in the name of Gemfin

A. Álvarez-Larrán

9:30 - 9:55

Challenges in path. diagnosis of MPNs in 2025

H.M. Kvasnicka

9:55 - 10:20

Triple negative MPNs – when driver mutations can’t guide you

T. Sacha

10:20 - 10:45

Rare chronic myeloid neoplasms

A. Reiter

10:45 - 11:10

Individual risk scores and machine learning

G. Abu-Zeinah

11:10 - 11:40

BREAK

SESSION 3

TREATMENT OF MPNS IN 2025

M. Sobas, A. Hatalová

11:40 - 12:05

Anticoagulation

M. Griesshammer

12:05 - 12:30

Rethinking risk-based treatment strategies in polycythemia vera

T. Barbui

12:30 - 12:55

Expectation from cytoreductive therapy in PV and ET

J.-J. Kiladjian

12:55 - 14:00

LUNCH BREAK

14:00 - 14:25

The right dose

H. Gisslinger

14:25 - 14:50

How to treat elderly/frail patients

H. Al-Ali

14:50 - 15:15

What more can be achieved with combination therapy?

H. Hasselbalch

15:15 - 15:45

BREAK

SESSION 4

EMERGING THERAPY CONCEPTS

J. Schwarz, I. Ursuleac

15:45 - 16:10

Do we need a specific approach based on the mutational status in ET?

A. Álvarez-Larrán

16:10 - 16:35

Progress in early clinical research in MPN

J. O’Sullivan

16:35 - 17:00

Are we ready for mutation-guided therapy?

J. Scandura